On February 24, 2026 Centauri Therapeutics Limited has closed the transaction. The company amended the terms of the transaction. The company has raised £6 million in its second and final tranche, bringing the total funding raised in the transaction to £30 million.

The transaction include participation from new investor AMR Action Fund, L.P. a fund managed by AMR Action Fund GP, LLC. The company has issued convertible preferred stock in the transaction.